

# STATISTICAL ANALYSIS PLAN (SAP)

Determining the longitudinal stability of plasma neurofilament light chain (NfL) in individuals at-risk for symptomatic FTLD through the Neurofilament Surveillance Project (NSP)

Sponsor: The Bluefield Project to Cure Frontotemporal Dementia

**Prepared by: Berry Consultants** 

**Document Version: Version 1.0** 

**Document Date: 9 December 2024** 

Company / Organization	Steering Committee Member	Signature
ADDF	Patricia Saletti	
Alector	Olga Kahn	Olga Kalin
ALLFTD	Adam Boxer	adam Boxer
Arkuda Therapeutics	Raymond Hurst	Raymond Hurst
Biogen	Danielle Graham	Darch Cor
The Bluefield Project to Cure FTD	Laura Mitic	Laura Mitic
Denali Therapeutics	Richard Tsai	DEEUStarraeDay24D4
Ionis Pharmaceuticals	Holly Kordasiewicz	Holly Cordasiewicz
Johnson & Johnson	Gallen Triana-Baltzer	Gallen Triana-Baltzer
Passage Bio	Sue Browne	Sw Browne
Rainwater Charitable Foundation	Glenn Harris	Segned 49E 3314A1 Slenn a. Harris
Takeda	Arthur Simen	Arthur Simen
UCB Biopharma	Ina Tesseur	Ina Tesseur
Verge Genomics	Rob Scannevin	

Company / Organization	Steering Committee Member	Signature
ADDF	Eli Shob	EXM
Alector	Olga Kahn	Olga kalur
ALLFTD	Adam Boxer	Illam Bossir
Arkuda Therapeutics	Raymond Hurst	Raymond Hurst
Biogen	Danielle Graham	Durch Car
The Bluefield Project to Cure FTD	Laura Mitic	Laura Mitic
Denali Therapeutics	Richard Tsai	Degas
Ionis Pharmaceuticals	Holly Kordasiewicz	Holly Eordasiewicz
Johnson & Johnson	Gallen Triana-Baltzer	Gallen Triana-Baltzer
Passage Bio	Sue Browne	Sue Browlase
Rainwater Charitable Foundation	Glenn Harris	Stern Q. Harris
Takeda	Arthur Simen	Arthur Simen
UCB Biopharma	Ina Tesseur	Ina Tesseur
Verge Genomics	Rob Scannevin	WAZ-

# **TABLE OF CONTENTS**

1	LIST OF ABBREVIATIONS
2	INTRODUCTION
3	STUDY DESCRIPTION
4	OBJECTIVES AND ENDPOINTS
4.1	OBJECTIVES
4.1.1	NFL CHARACTERIZATION
4.1.2	ASSOCIATION WITH CLINICAL AND NEUROIMAGING MEASURES
4.2	SCHEDULE OF ASSESSMENTS
4.3	ENDPOINTS
4.3.1	PRIMARY ENDPOINT
4.3.2	CLINICAL CORRELATE ENDPOINTS
4.3.3	MRI CORRELATE ENDPOINTS
4.3.4	COVARIATES OF INTEREST
4.3.5	MISSING DATA
5	ANALYSIS POPULATION
5.1	PRIMARY ANALYSIS POPULATION
6	STATISTICAL ANALYSES 10
6.1	CHARACTERIZATION OF ENROLLED POPULATION
6.2	CHARACTERIZATION OF NFL
6.2.1	EXPECTED PROGRESSION
6.2.1.1	FIGURES AND TABLES
6.2.1.2	REPEATED MEASURES ANALYSIS OF NFL
6.2.2	VARIABILITY
6.3	ASSOCIATION OF NFL WITH CLINICAL AND MRI PROGRESSION
6.3.1	CORRELATION
6.3.2	PREDICTION OF FUTURE RATES OF CLINICAL PROGRESSION
6.3.3	PREDICTION OF SYMPTOMATIC CONVERSION
6.4	ANALYSIS SCHEDULE
6.4.1	INTERIM ANALYSES
6.4.2	FINAL ANALYSES
6.4.3	ANALYSIS TABLES

#### 1 LIST OF ABBREVIATIONS

Abbreviation or	Explanation
Special Term	
AE	Adverse event
ALLFTD	ARTFL-LEFFTDS Longitudinal Frontotemporal Lobar
	Degeneration
ARTFL-LEFFTDS	Advancing Research and Treatment for FTLD-Longitudinal
	Evaluation of Familial FTLD Syndromes
BMI	Body Mass Index
CDR	Clinical Dementia Rating (CDR®) Dementia Staging Instrument
CDR®+NACC-FTLD	CDR Dementia Stage Instrument PLUS National Alzheimer's
	Coordinating Center (NACC) Behavior and Language Domains
CDR®+NACC-FTLD-SB	CDR®+NACC-FTLD Sum of Boxes
f-FTLD	Familial frontotemporal lobar degeneration
FTD	Frontotemporal dementia
FTLD	Frontotemporal lobar degeneration
LME	Linear mixed effects
MINT	Multilingual Naming Test
MoCA	Montreal Cognitive Assessment Test
MRI	Magnetic resonance imaging
NfL	Neurofilament light chain
NHS	Natural history study
NSP	Neurofilament Surveillance Project
ROI	Region of interest
SAP	Statistical analysis plan
TIV	Total intracranial volume
UDS3-EF	Uniform Data Set v3.0 Executive Function

## 2 INTRODUCTION

This statistical analysis plan (SAP) describes the analysis for the Neurofilament (NfL) Surveillance Project (NSP) in participants from families with identified pathogenic FTLD mutations who have or are at-risk for symptomatic frontotemporal lobar degeneration (FTLD), including family members who do not carry the mutation. FTLD is a heterogenous group of neurodegenerative diseases. The SAP defines the analysis population and prespecifies the statistical methods for analyzing the longitudinal NfL measurements in plasma collected through the NSP. Analyses aim to understand the stability of NfL collected every 3 months over a 36-month time period through the description and quantification of NfL measurements, as well as the correlation of NfL measurements with other outcome measures, including clinical, cognitive, and magnetic resonance imaging (MRI) measurements collected through ALLFTD.

## **3 STUDY DESCRIPTION**

The Neurofilament Surveillance Project (NSP) is a precompetitive consortium whose goal is to prepare for pivotal clinical trials aimed at the prevention of familial FTLD (f-FTLD) by characterizing NfL levels during disease onset and progression. The NSP enrolled 342 participants who will donate blood at home every 3 months for 3 years. This study differs from other ongoing natural history studies (NHS) because of the increased frequency of NfL measurements and the investigation into the feasibility of collecting NfL samples remotely. Increased frequency of NfL measurements has the potential to improve the power to detect symptomatic disease onset, while remote NfL sample collection has the potential to improve monitoring of individuals at-risk for FTLD. The analyses set forth in this SAP will explore longitudinal NfL data collected remotely through the NSP to assess how NfL can be better leveraged to improve the treatment of FTLD.

## **4 OBJECTIVES AND ENDPOINTS**

#### 4.1 **OBJECTIVES**

We will focus on the following objectives from the study protocol.

#### 4.1.1 NFL CHARACTERIZATION

- The primary objective of the NSP is to determine the longitudinal stability of plasma NfL measured every 3 months for 36 months in individuals at-risk for symptomatic FTLD.
- Additionally, an objective of the NSP is to assess the pre-analytic (ex. batch, assay lot number, assay run, storage time and collection time), analytic, and within subject variability associated with plasma NfL measurements on a standard, commercially available Single Molecule Array (Simoa) platform.

#### 4.1.2 ASSOCIATION WITH CLINICAL AND NEUROIMAGING MEASURES

• An additional objective of the NSP is to evaluate ALLFTD collected clinical and magnetic resonance imaging (MRI) neuroimaging measures with plasma NfL levels in asymptomatic and symptomatic f-FTLD mutation carriers.

## 4.2 SCHEDULE OF ASSESSMENTS

Blood and a limited set of data will be collected from NSP participants every 3 months over the course of 3 years. Data collected include concomitant medications, interim changes in health, and adverse events.

In addition to data collected within the NSP study, the following data will be collected annually on NSP participants as part of ALLFTD, and data from the ALLFTD visits will be obtained for the NSP database.

- Medical history (history of HIV, peripheral neuropathy, traumatic brain injury, chronic kidney disease, atrial fibrillation, stroke, liver failure, renal failure)
- Vital signs (height, weight, Body Mass Index (BMI))
- Demographics (e.g., years education, age in 5 year intervals, sex)
- Clinical measures
- MRI Volumetric measures

All longitudinal data collected through NSP and specified variables collected through ALLFTD on these participants will be used for the purpose of analyses. Baseline visit will be defined as the first NSP visit. Baseline information required in analyses and for definitions of subgroups that are only available through ALLFTD visits (ex. CDR®+NACC-FTLD-Global) will be taken from the ALLFTD visit closest to the baseline NSP visit. If two consecutive ALLFTD visits are the same distance from the baseline NSP visit, baseline information will be taken from the earlier ALLFTD visit. A summary of the lag time between the ALLFTD visit used for baseline covariates and the baseline NSP visit will be included.

# 4.3 ENDPOINTS

Several types of endpoints will be defined to address the objectives on NfL characterization and correlation with clinical and neuroimaging measures. The primary endpoint will be used to characterize NfL, while the correlate endpoints will be used to explore the correlation of NfL with clinical and neuroimaging measures. Covariates of interest are defined below in section 4.3.4, which may be of interest when characterizing NfL and/or exploring the correlation of NfL with the correlate endpoints.

# 4.3.1 PRIMARY ENDPOINT

The primary endpoint of the NSP is NfL from plasma samples. NfL will be log transformed for all analyses. Data on this endpoint will be collected from baseline to 36 months in each participant within NSP.

Additional NfL levels from plasma samples collected through ALLFTD visits may be provided. Depending on data availability, these values will be included within a secondary analysis of NfL that investigates potential differences in NfL across different studies (ALLFTD vs. NSP).

# 4.3.2 CLINICAL CORRELATE ENDPOINTS

The relationship between NfL and several clinical measures will be explored. Primary clinical measures of interest, and their association with NfL, will be analyzed during interim analyses. One interim analysis will be conducted after each data delivery. The results for analyses with the primary clinical measures will be included in the interim results. The relationship between NfL and the secondary clinical measures listed below will only be included in the final analysis.

## • Primary clinical measures of interest:

- o CDR®+NACC-FTLD-SB
- CDR®+NACC-FTLD-SB + Motor
- Uniform Data Set v3.0 Executive Function (UDS3-EF) Composite Score

## • Secondary clinical measures of interest:

- Montreal Cognitive Assessment Test (MoCA)
- Trail Making Test, Part A
- Trail Making Test, Part B
- Multilingual Naming Test (MINT)
- o Animal Fluency
- Vegetable Fluency
- Lexical Fluency (F&L words)

# 4.3.3 MRI CORRELATE ENDPOINTS

The relationship between NfL and a number of MRI outcome measures will be explored. Primary MRI measures of interest, and their association with NfL, will be analyzed during interim analyses. The results for analyses with the primary MRI measures of interest will be included in the interim results. The relationship between NfL and the secondary MRI measures of interest listed below will only be included in the final analyses. All MRI measures will use the Desikan-Killany atlas and each region of interest (ROI) will be adjusted for by total intracranial volume (TIV). MRI regions will be a bilateral composite, by default, although we will explore approaches that consider asymmetric atrophy which may reduce the associations observed with bilateral composites.

## • Primary MRI measures of interest:

- Frontal lobe
- Temporal lobe

## • Secondary MRI measures of interest:

- o Striatum
- o Parietal lobe
- o Thalamus
- o Putamen
- o Insula
- o Cerebellum
- o Ventricular Volume
- o Laterality index

### 4.3.4 COVARIATES OF INTEREST

Covariates of interest are defined, which may be used to explore or explain heterogeneity in NfL and/or the relationship of NfL with the correlate endpoints. A table of baseline covariates and time-varying covariates at baseline for the enrolled population will be provided together with baseline values of NfL (Table 1). In addition, Table 1 will include a summary of the lag time (days) between the ALLFTD visit used for baseline covariates and the baseline NSP visit.

#### • Baseline covariates

- o Sex
- o Onset Age
- CDR®+NACC-FTLD-Global
- Mutation status (*GRN* only, *C9orf72* only, *MAPT* only, or Control)
  - Controls defined as participants with no known mutation and CDR®+NACC-FTLD-Global=0
  - Participants with no known mutation and CDR®+NACC-FTLD-Global >0 will be classified as "Symptomatic unknown cause"
- Family Mutation (GRN, C9orf72, MAPT)
- Presence of *TMEM106B*+ mutation
- Presence of motor symptoms based on clinical syndrome (ALS, FTD with motor neuron disease, CBS, PSP)
- Disease Age estimated from disease progression model<sup>1</sup>
- Time-varying covariates
  - Chronological Age
  - o BMI
  - Major changes in health (moderate or severe AEs experienced since last visit; specific events of interest including new diagnoses of HIV, peripheral neuropathy, traumatic brain injury, chronic kidney disease, atrial fibrillation, stroke, liver failure, renal failure, accidents involving a vehicle, AEs due to a fall, and all AEs rated a serious or severe unless related to the progression of FTD.)
  - Vaccination status (vaccine within preceding three months)
  - NfL measurement information including:
    - Batch
    - Assay lot number (Quanterix kit number)
    - Assay run
    - Storage time
    - Collection time

<sup>&</sup>lt;sup>1</sup> Staffaroni AM, et al., Frontotemporal Dementia Prevention Initiative (FPI) Investigators. Temporal order of clinical and biomarker changes in familial frontotemporal dementia. Nat Med. 2022 Oct;28(10):2194-2206. doi: 10.1038/s41591-022-01942-9. Epub 2022 Sep 22. PMID: 36138153; PMCID: PMC9951811.

## 4.3.5 MISSING DATA

Missing data for the primary endpoint, clinical and MRI correlates, and covariates will be characterized using tables showing the proportion of missingness by visit. For the primary endpoint, clinical and MRI correlates, and time-varying covariates tables of missingness patterns across visits will be produced to enumerate the number of participants with complete data, loss to follow-up, and intermittent drop out.

Summary tables which are reported using a subgroup which contains missing values will include a 'missing' category.

As this is an observational study, complete case analysis will be used for all outcome variables (Clinical and MRI correlations) and time-varying covariates. Continuous baseline covariates, if missing, will be imputed based on the median when included as a covariate in an analysis. Missing categorical baseline covariates will be assigned to a separate "missing" category when included as a covariate. Participants with missing baseline covariate information used to define a subgroup status will be excluded from the subgroup analysis.

# 5 ANALYSIS POPULATION

## 5.1 PRIMARY ANALYSIS POPULATION

The primary analysis population is a cohort of f-FTLD participants already enrolled in ALLFTD, who are receiving quarterly home blood draws. Participants can be male or female, ages 18-85, and are members of a family with a known mutation in *C9orf72, GRN* or *MAPT*, including those with an individual mutation status of *GRN* only, *C9orf72* only, *MAPT* only or no known individual mutation and FTLD-CDR Global=0 (Control). Participants with 'Other' or 'Unknown' family mutation (including multiple family mutations such as '*C9orf72* and *GRN'*) and those with no known mutation and CDR®+NACC-FTLD-Global >0 (Symptomatic Unknown Cause) will be excluded from the primary analysis population. All specified analyses will be conducted on this primary analysis population, unless otherwise specified.

Some analyses will be repeated for specified subgroups of interest, after they have been conducted on the primary analysis population. The subgroups of interest will be defined by:

- Symptomatic status: Asymptomatic (Baseline CDR®+NACC-FTLD-Global =0); Pre-symptomatic (Baseline CDR®+NACC-FTLD-Global =0.5); and Symptomatic (Baseline CDR®+NACC-FTLD-Global >=1)
- 2) Mutation type (*C9orf72* only, *GRN* only, *MAPT* only, or Control)
- 3) Data collection type (ALLFTD vs NSP). Primary analyses will be conducted using NfL data collected through the NSP. Based on data availability, sensitivity analyses may also include NfL Data from ALLFTD.

## 6 STATISTICAL ANALYSES

#### 6.1 CHARACTERIZATION OF ENROLLED POPULATION

The baseline demographic and clinical characteristics of the enrolled population will be summarized in a table (Table 1) with covariates of interest described in section 4.3.4 including lag time between the ALLFTD visit used for baseline covariates and the baseline NSP visit. Summary tables stratified by symptomatic status and mutation type will also be produced.

## 6.2 CHARACTERIZATION OF NFL

## 6.2.1 EXPECTED PROGRESSION

The expected longitudinal progression of NfL will be summarized using the figures, tables, and analyses outlined in the following sections. The primary goal is to understand the progression of longitudinal NfL measurements in the primary analysis population, as well as by subgroups of interest (Section 5.1).

## 6.2.1.1 FIGURES AND TABLES

## Spaghetti plots

Spaghetti plots will be created, which show individual trajectories of:

- A) log NfL values over time (months since baseline)
- B) log NfL change from baseline values over time (months since baseline)

Points will be color-coded by symptomatic status. If ALLFTD NfL data is included, different plotting symbols will be used for data collection type (ALLFTD vs. NSP). Plots will be shown overall and separately based on mutation type.

## Data Summaries

The log NfL values will be summarized across visits (binned in 3-month intervals) by mutation and symptomatic status in the following ways:

- A) log NfL values by visit: Mean (SD), Median (1<sup>st</sup> quartile, 3<sup>rd</sup> quartile), Minimum, Maximum
- B) log NfL change from baseline values by visit: Mean (SD), Median (1<sup>st</sup> quartile, 3<sup>rd</sup> quartile), Minimum, Maximum

One table will be created overall and separately for each mutation status. Within each table, columns will be provided for overall population and within each symptomatic group.

# Scatterplot Matrix

A scatterplot matrix will be created to show the pairwise relationship between log NfL values at each visit:

A) log NfL values by visit (baseline vs. visit 1, baseline vs. visit 2, baseline vs. visit 3, baseline vs. visit 4, ..., visit 2 vs. visit 3, visit 2 vs. visit 4, etc.)

B) log NfL baseline vs change from baseline by visit (baseline vs. change from baseline at visit 1, baseline vs. change from baseline at visit 2, baseline vs. change from baseline at visit 3, baseline vs. change from baseline at visit 4, ..., change from baseline at visit 1 vs. change from baseline at visit 2, change from baseline at visit 1 vs. change from baseline at visit 2, change from baseline at visit 1 vs. change from baseline at visit 3, etc.)

The scatterplot matrices will also report Pearson's correlation coefficients and Spearman's rank correlation coefficients for each pairwise comparison. These analyses will be conducted overall and separately by mutation and symptomatic status.

# 6.2.1.2 REPEATED MEASURES ANALYSIS OF NFL

A repeated measures analysis of NfL from baseline to 36 months will be conducted using a linear mixed effects (LME) model with subject-level random intercepts and random slopes. Time of visit will be treated as continuous. Main (fixed) effects and main effect by time interactions will be included for baseline covariates. Variable selection will be performed by exploring all  $2^8 = 256$  distinct subsets of baseline covariates (from the set listed in Section 4.3.4). In addition, to adjust for the lag time between the ALLFTD visit used for baseline covariates and the baseline NSP visit, the number of days between these visits will be included as a covariate in all models with a baseline covariate from ALLFTD that can change over time (e.g., CDR®+NACC-FTLD-Global). The final set of baseline covariates will be determined using Akaike information criterion (AIC). For all baseline covariates in the final set, two-way interactions will also be explored. At the final analysis, several sensitivity analyses will be performed. To explore potential serial correlation, the first sensitivity analysis will model random variation by including a serial correlation term in addition to random effects and measurement error. To better understand the shape of progression for NfL, the second sensitivity will explore two potential functional forms of the time covariate: time categorical and cubic splines.

# 6.2.2 VARIABILITY

The repeated measures analysis of NfL defined within Section 6.2.1.2 will provide overall estimates of within-subject variability (measurement error and serial correlation) and across subject variability of NfL at baseline (variability in intercept) and over time (variability in slope). Within this section on NfL variability, possible additional explanations of within-subject variability (measurement error) will be explored using time-varying covariates.

The following non-biological sources of variation will be explored: collection type (NSP remote vs. ALLFTD in clinic), batch, assay lot number, assay run, storage time, and collection time.

Boxplots of baseline NfL by batch, assay lot number, and assay run will be produced to assess inter-run variation.

The following biological sources of variation will be explored: chronological age, BMI, changes in BMI, changes in health, and proximity to vaccination.

For each assessment of variation, standardized residuals from the model in Section 6.2.1.2 will be plotted vs. the value of the time-varying covariate. Additionally, the repeated measures analysis defined in Section 6.2.1.2 will be repeated with the inclusion of the time-varying covariate as a fixed effect. All single-variable models will be explored (one time-varying covariate at a time). Mean covariate effect estimates will be reported as well as reductions in residual standard error when including the covariate. Covariate variable selection will be conducted using a step-down Akaike information criterion (AIC) procedure and a final model will be reported.

In addition, standardized residuals from the final model and corresponding time differences will be used to estimate a sample variogram for the primary endpoint.

An outlier analysis will also be conducted. NfL values will be flagged as abnormal fluctuations if the absolute standardized residual from the model in Section 6.2.1.2 is larger than 3 standardized units. Summaries of biological and non-biological (Mean; SD if continuous vs. proportions if dichotomous) potential sources of variation will be provided for all NfL values flagged as abnormal fluctuations vs. those not flagged as abnormal. If a substantial number of outliers are detected (greater than 5%), sensitivity analyses will be performed with outliers removed. Outliers will also be flagged in plots.

# 6.3 ASSOCIATION OF NFL WITH CLINICAL AND MRI PROGRESSION

## 6.3.1 CORRELATION

Both cross-sectional and longitudinal correlations will be assessed individually for each clinical and MRI correlate defined in Sections 4.3.2 and 4.3.3. To explore correlations controlling for covariate effects, subject level deviations from the population mean (random intercepts) will be estimated for each participant from repeated measures models as defined in Section 6.2.1.2 replacing NfL as the outcome of interest with each potential correlate endpoint. Similarly, to assess longitudinal correlations, rates of progression (random slopes) for each endpoint will also be estimated for each participant from the repeated measures models.

For each correlate endpoint the following will be performed:

Plot of baseline NfL values vs. baseline values of the potential correlate.
 Points will be colored based on mutation and different shapes will be used to denote symptomatic status. Pearson's correlation coefficients and Spearman's rank correlation coefficients will be reported by mutation and symptomatic status.

- Plot of NfL random intercepts vs. random intercepts of potential correlate. Points will be colored based on mutation and different shapes will be used to denote symptomatic status. Pearson's correlation coefficients and Spearman's rank correlation coefficients will be reported by mutation and symptomatic status.
- Plot of baseline NfL values vs. rate of progression of potential correlate. Points will be colored based on mutation and different shapes will be used to denote symptomatic status. Pearson's correlation coefficients and Spearman's rank correlation coefficients will be reported by mutation and symptomatic status.
- Plot of rate of change in NfL vs. rate of change of potential correlate. Points will be colored based on mutation and different shapes will be used to denote symptomatic status. Pearson's correlation coefficients and Spearman's rank correlation coefficients will be reported by mutation and symptomatic status.

Additionally, to explore changes in correlation between NfL and clinical and MRI correlates over time, a bivariate repeated measures analysis will be used. The bivariate model is constructed by linking the NfL and correlate repeated measures models together via a joint distribution of random effects. The joint random effects distribution is assumed to be normally distributed with mean vector (0,0,0,0) and covariance matrix estimating variance of all four random effects (NfL and correlate random intercepts and NfL and correlate random slopes) as well as all covariances. The error terms are assumed to follow a bivariate normal distribution with mean vector (0,0) and uncorrelated errors between NfL and the correlate. In particular, let the covariance of the random effects be

$$\begin{bmatrix} \sigma_{a_1}^2 & \sigma_{a_1a_2} & \sigma_{a_1b_1} & \sigma_{a_1b_2} \\ & \sigma_{a_2}^2 & \sigma_{a_2b_1} & \sigma_{a_2b_2} \\ & & \sigma_{b_1}^2 & \sigma_{b_1b_2} \\ & & & & \sigma_{b_2}^2 \end{bmatrix}$$

and  $\sigma_1^2$  and  $\sigma_2^2$  be the variances of the residual error terms for the NfL and correlate, then the marginal correlation at time *t* is calculated as

$$\rho_m(t) = \frac{\sigma_{a_1 a_2} + t \sigma_{a_1 b_2} + t \sigma_{a_2 b_1} + t^2 \sigma_{b_1 b_2}}{\sqrt{\sigma_{a_1}^2 + 2t \sigma_{a_1 b_1} + t^2 \sigma_{b_1}^2 + \sigma_1^2} \sqrt{\sigma_{a_2}^2 + 2t \sigma_{a_2 b_2} + t^2 \sigma_{b_2}^2 + \sigma_2^2}}$$

#### 6.3.2 PREDICTION OF FUTURE RATES OF CLINICAL PROGRESSION

A longitudinal k-means clustering analysis will be conducted using CDR®+NACC-FTLD-SB values over time to cluster participants based on post-baseline clinical rate of progression. This generalization of the k-means algorithm will be used to assess CDR®+NACC-FTLD-SB trajectories by shape. Baseline NfL values and changes in NfL will be summarized for each cluster overall and within each cluster by mutation status to explore NfL as a potential explanatory variable for heterogenous progression. The optimal number of clusters to be used in the clustering analysis will be explored using the elbow, average silhouette, and gap statistic methods.

In addition, clustering will be visualized with plots of CDR®+NACC-FTLD-SB over time. The following will be performed:

- Overall plot of CDR®+NACC-FTLD-SB vs. time with points and lines colored by cluster.
- Plots of CDR®+NACC-FTLD-SB vs. time stratified by tertiles of baseline NfL (bottom, middle, or upper) with points and lines colored by cluster.
- Plots of CDR®+NACC-FTLD-SB vs. time stratified by mutation type (*C9orf72* only, *GRN* only, *MAPT* only, or Control) with points and lines colored by cluster.
- Plots of CDR®+NACC-FTLD-SB vs. time stratified by tertiles of change from baseline NfL (bottom, middle, or upper) with points and lines colored by cluster.

# 6.3.3 PREDICTION OF SYMPTOMATIC CONVERSION

This analysis will be conducted on all participants who are asymptomatic (CDR®+NACC-FTLD-Global of 0) or pre-symptomatic (CDR®+NACC-FTLD-Global of 0.5) at baseline NSP visit. Participants will be grouped into those who are converters (increase from a baseline CDR®+NACC-FTLD-Global score < 1 to a CDR®+NACC-FTLD-Global of >=1 at any point within the time period) vs. nonconverters. Conversion will be defined for three pre-specified time periods (conversion within 1 year, 2 years or 3 years). Baseline NfL values (mean, SD, median, 1<sup>st</sup> quartile, 3<sup>rd</sup> quartile, minimum, maximum) will be summarized for converters vs. non-converters at each time point by mutation status. ROC curves and corresponding AUC values will be calculated to show sensitivity and specificity of different NfL cutoffs for predicting future conversion at the different time periods overall and by mutation status. A sensitivity analysis will exclude any participants who convert and then show a CDR®+NACC-FTLD-Global score of < 1 at a subsequent timepoint.

In addition, a time to event analysis will be performed using interval-censored time to first conversion (CDR®+NACC-FTLD-Global >=1). Kaplan-Meier plots of time to conversion stratified by quintiles of baseline NfL will be produced and summaries of the probability of remaining asymptomatic or pre-symptomatic at 1 year, 2 years, and 3 years will be shown.

Depending on availability of suitable data, the association between symptomatic conversion and other functions of NfL (e.g., age-adjusted baseline NfL z-scores) may be explored by summarizing values for converters vs. non-converters.

#### 6.4 ANALYSIS SCHEDULE

#### 6.4.1 INTERIM ANALYSES

Interim analyses of available data will occur throughout the study, after each data delivery. These interim analyses will begin after the SAP is finalized. Interim analyses will contain a subset of the specified statistical analyses, including Sections 6.2.1 and Section 6.3.1 for the defined primary clinical and primary MRI potential correlate outcomes. The other specified statistical analyses will only be conducted during the final analyses. Results from interim analyses will be provided in an interim analysis report.

#### 6.4.2 FINAL ANALYSES

The final analyses will be conducted when the last participant has had the opportunity to complete their final visit at three years. All analyses detailed in Section 6.2 and Section 6.3 will be conducted during the final analyses.

#### 6.4.3 ANALYSIS TABLES

Here we enumerate the analyses that will be conducted and specify which analyses will be conducted at the interim vs. only at the final analysis.

Section 4.3 results in a total of 5 Tables. Section 6.2 results in a total of 35 Figures, 11 Tables, and 13 Analyses. Section 6.3 results in a total of 108 Figures, 3 Tables, and 41 Analyses.

Count	Section	Analysis Description	Population	Endpoint	Performed at Interim
Table 1 a -c (3)	4.3.4 Baseline Demographics and Clinical Characteristics	Summary of Enrolled population	Overall (Table 1a) and by symptomatic status (Table 1b) and mutation status (Table 1c)	Covariates	X
Table 2	4.3.5 Missing Data	Proportion of Missingness by visit	All data	NfL, covariates, correlates	Х
Table 3		Missingness patterns across visits	All data	NfL, time-varying covariates, correlates	
Fig 1 a-j (10)	6.2.1 Changes in NfL	Spaghetti plots NfL	Overall (Fig 1a) and by mutation status (Fig 1b,c,d,e). Color code based on symptomatic status.	NfL	X
			Overall (Fig 1f) and by mutation status (Fig 1g,h,i,j). Color code based on symptomatic status.	Change in NfL	X
Table 4 a-j (10)		Summary Tables NfL by mutation and symp. status	Overall (Table 4a) and by mutation status (Table 4b,c,d,e). Columns for each symptomatic status and total.	NfL	X
			Overall (Table 4f) and by mutation status (Table 4g,h,i, j). Columns for each symptomatic status and total.	Change from baseline NfL	X
Fig 2 a-j (10)		Scatterplot Matrix with correlation coefficients	Overall (Fig 2a) and by mutation status (Fig 2b,c,d,e). Color code based on symptomatic status.	NfL	

			Overall (Fig 2f) and	Change in NfL	
			by mutation status		
			(Fig 2g,h,i,j). Color		
			code based on		
			symptomatic		
			status.		
Analysis 1		LME Analysis of NfL	Overall	NfL, covariates	Х
Fig 3	6.2.2	Residual plot of NfL vs.	Overall	NfL, Collection type	
a-j	Variation of	time-varying covariate		NfL, Batch	
(11)	NfL			NfL, Assay lot number	
				NfL, Assay run	
				NfL, Storage time	
				NfL, Collection time	
				NfL, Chronological Age	
				NfL, BMI	
				NfL, Change in BMI	
				NfL, Change in Health	
				NfL, Vaccination	
Analysis 2 a-k		LME Analysis of NfL	Overall	NfL, Collection type	
(12)		covariate adjusted		NfL, Batch	
				NfL, Assay lot number	
				NfL, Assay run	
				NfL, Storage time	
				NfL, Collection time	
				NfL, Chronological Age	
				NfL, BMI	
				NfL, Change in BMI	
				NfL, Change in Health	
				NfL, Vaccination	
				NfL, + all time-varying cov.	
				w/ variable selection	
Fig 4 a-c		Boxplots	Overall	Baseline NfL, Batch	
(3)				Baseline NfL, Assay lot	
				number	
				Baseline NfL, Assay Run	
Fig 5	]	Sample Variogram	Overall	NfL residuals	
Table 5		Outlier Analysis of NfL	Overall	NfL + all time-varying cov.	

Analysis 3 a - S (20)     6.3.1 Correlation with ML and Clinical + MRI Endpoints     LME analysis of potential correlates to estimate subject-level random intercept and rate of change + MRI Endpoints     Overall CDR®+NACC-FTLD-SB     CDR@+NACC-FTLD-SB       Fig 6-9 a-s (80)     • Piot of baseline ML vs. baseline potential correlate + orrelation coef. • Piot of baseline ML vs. baseline potential correlate + correlation coef. • Piot of baseline ML vs. remporal MRI ROI     0     Verall     CDR@+NACC-FTLD-SB     X       CDR@+NACC-FTLD-SB     X     MRI Correlates Secondary (7)     X       • Piot of baseline ML vs. baseline potential correlate + correlation coef. • Piot of baseline ML vs. rate of progression NL vs. rate of progression NL vs. rate of progression NL vs. rate of progression NL vs. rate of progression between subject-level random intercepts and rates of change and their correlate + correlation coef.     Overall     NRL Correlates Secondary (8)       Fig 10 a-s (20)     6.3.2 Table 6     Classeline ML sus; MIL and potential correlate + correlation coefs.     Overall     NRL, Clinical and MRI Correlates (20)     NRL Temporal MRI ROI     X       Fig 11 a - d (4)     Fig 11 a - d (4)     Fig 11 N, table Fig 11 N, table 7     Classeline mJNL summary of NRL (baseline progression progression progression progression of Rate of correlate very NRL (baseline and rate of change) by cluster overall and by baseline NRL, mutation type, and change from baseline ML baseline NRL (baseline progression of Rate of converters vs. non- correlate very NRL (baseline and rate of change) by cluster overall and by baseline NRL (baseline progression progression of Rate of converters vs. non- converters vs	Count	Section	Analysis Description	Population	Endpoint	Performed at
Analysis 3 ars (20)       0.5.1 Correlation with NR, and Clinical + MRI Endpoints       Definition with NR, and Clinical + MRI Endpoints       Definition with NR, and Clinical + MRI Endpoints       Definition with NR, and Clinical + MRI Endpoints       Definition with NR, and Clinical + MRI Endpoints       Definition + MRI + Plot of baseline NL vs. baseline potential correlate + correlation coef.       Overall       Definition + CRR®+NACC-FTLD-SB + Motor + Correlate Secondary (8)       -         Fig 6-9 a-s (80)       • Plot of baseline NL vs. baseline potential correlate + correlation coefs.       Overall + CRR®+NACC-FTLD-SB + Motor + Correlation coefs.       Verall + COR®+NACC-FTLD-SB + Motor - Plot of Saseline NL vs. recorrelation coefs.       Overall UDS3-EF Composite Score X       Verall - CDR®+NACC-FTLD-SB + Motor - COR®+NACC-FTLD-SB + Motor - COR®+NACC-FTLD-SB + Motor - Correlation coefs.         Analysis 4 a-s (20)       • Plot of Saseline NL vs. rate of progression potential correlate + correlation coefs.       Overall - Correlate Secondary (8)       X         Fig 10 a-s (20)       • Plot of marginal correlate + correlation coefs.       Overall - NIL, Strate of progression potential correlate + correlation coefs.       NIL - Correlate - Correlate - Correlation between NL and potential correlate over time - Correlation - Correlation -	Analysis 2 a.a.	621	IME analysis of notantial	Orronall		Interim
(10)       Contraction       Contraction       A         with ML and Clinical + MRI Endpoints       Subject-level random intercept and rate of change       Contract of Contracts Secondary (7)       A         Fig 6-9 a-s (80)       • Plot of baseline NL vs. baseline potential correlate + correlation coef.       Overall       CDR@+NACC-FTLD-SB       X         Fig 10 a-s (20)       • Plot of baseline NL vs. baseline potential correlate + correlation coef.       Overall       CDR@+NACC-FTLD-SB       X         Fig 10 a-s (20)       • Plot of baseline NL vs. rate of progression potential correlate + correlation coef.       Overall       CDR@+NACC-FTLD-SB       X         Fig 10 a-s (20)       • Plot of baseline NL vs. rate of progression potential correlate + correlation coef.       Overall       NRI. Correlates Secondary (7)       Clinical Correlates Secondary (7)         Fig 10 a-s (20)       • Plot of rate of progression potential correlate + correlation coef.       Overall       NRI. Correlates Secondary (8)       NI         Fig 10 a-s (20)       • Plot of marginal correlate correlation       Overall       NR. Clinical and MRI Correlates (20)       Image in their covariance for marginal correlation       Overall       NR. Clinical and MRI Correlates (20)       Image in their covariance for marginal correlate over time       Overall       NR. Clinical and MRI Correlates (20)       Image in their covariance for marginal correlate over time       Overall       NR. Clinical	(20)	Correlation	correlates to estimate	Overall	CDR@+NACC_FTLD_SB + Motor	A V
and Clinical + Mil Endpoints     intercept and rate of change intercept and rate of change     Discal Correlates Secondary (7) Frontal MRI ROI     X       Fig 6-9 a-s (80)     • Plot of baseline NR.vs. baseline potential correlate + correlation coef.     Overall     Overall     CDR@+NACC-FTLD-SB     X       • Plot of NR. random intercept vs. random intercept vs. random intercept potential correlate + correlation coefs.     Overall     Overall     CDR@+NACC-FTLD-SB + Motor     X       • Plot of NR. random intercept vs. random i	(20)	with Nfl.	subject-level random		UDS2_EE Composito Scoro	л V
+ MRI Endpoints     + MRI Endpoints     - Phot of baseline NfL vs. baseline potential correlate + correlation coef.     - Phot of baseline NfL vs. baseline potential correlate + correlation coef.     - Phot of baseline NfL vs. baseline potential correlate + correlation coef.     - Phot of baseline NfL vs. baseline potential correlate + correlation coef.     - Overall     - CDR®+NACC-FTLD-SB     X       - Phot of baseline NfL vs. baseline potential correlate + correlation coef.     - Phot of baseline NfL vs. rate of progression potential correlate + correlation coef.     - Phot of baseline NfL vs. rate of progression potential correlate + correlation coef.     - Phot of baseline NfL vs. rate of progression potential correlate + correlation coef.     - Phot of rate of progression potential correlate + correlation coef.     - Phot of rate of progression potential correlate for estimate correlations coef.     - Phot of RL vs. rate of charge and their covariance for marginal correlate on correlation correlations between subject-level random intercepts and rates of charge and their covariance for marginal correlate over time     - NL (20)     NL, Clinical and MRI Correlates (20)     - Phot of NL pase (20)       Fig 10 a-s (20)     6.3.2 NL endpotential correlate for of charge and their covariance for marginal correlation     - Overall     NR, CDR@+NACC-FTLD-SB		and Clinical	intercent and rate of change		Clinical Correlates Secondary (7)	Λ
Fig 6-9 a-s (80)     Pilot of baseline NL vs. baseline potential correlate + correlation coef. orrelation coef.     Overall     CDR@+NACC-FTLD-SB     X       Fig 10 a-s (20)     Pilot of baseline NL vs. baseline potential correlate + correlation coef.     Overall     CDR@+NACC-FTLD-SB     X       Analysis 4 a-s (20)     Pilot of baseline NL vs. rate of progression potential correlate + correlation corefate + correlation correlate - correlation potential correlate + correlation correlation potential correlate + correlation correlation potential correlate - correlation correlation potential correlate - correlation correlation potential correlate - correlation potential correlate - correlation correlation potential correlate - correlation correlation potential correlate - correlation potential		+ MRI	inter copt and tate of change		Frontal MRI ROI	x
Fig 6-9 a-s     MRI Correlates Secondary (8)     X       Fig 6-9 a-s     Overall     CDR@+NACC-FTLD-SB     X       (80)     - Plot of baseline potential correlate + correlation coef.     - Plot of NL random intercept sys. random		Endpoints			Temporal MRI ROI	X
Fig 6-9 a-s (80)       • Plot of baseline NfL vs. baseline potential correlate + correlation coef.       Overall       ORG@+NACC-FTLD-SB       X         • Plot of NI. random intercept potential correlate + correlation coefs.       • Plot of baseline NfL vs. reptot for fate of progression potential correlate + correlation coefs.       • Overall       ORG@+NACC-FTLD-SB       X         Analysis 4 a-s (20)       • Plot of fate of progression potential correlate to correlate ate - correlation coefs.       Overall       Overall       NfL Clinical and MRI Correlates (20)       X         Fig 10 a-s (20)       6.3.2       Bivariate LME Analysis of NfL and potential correlate to estimate correlation covariance for marginal correlate - correlation covariance for marginal correlation       Overall       NfL, Clinical and MRI Correlates (20)       NfL, Clinical and MRI Correlates         Fig 10 a-s (20)       6.3.2       Cluster Analysis       Overall       NfL, Clinical and MRI Correlates (20)       S         Fig 11 a - d (4)       Source and change progression of represention       Cluster overall and by baseline ML, mutation type, and change from baseline ML       Nor- symptomatic       NfL, CDR@+NACC-FTLD-SB         Table 7       6.3.3 NL Prediction of Conversion       Summary of ML (baseline) for converters vs. non- converters vs. non- converte					MRI Correlates Secondary (8)	Λ
(80)     International correlation     International correlation     International correlation     International correlation       (80)     International correlation     International correlation     International correlation     International correlation       (80)     International correlation     International correlation     International correlation     International correlation       (20)     International correlation     International correlation     International correlation     International correlation       (20)     Internation coef.     Internation coef.     Internation coef.     International correlation       Internation coef.     Internation coef.     Internation coef.     Internation coef.     International correlation       Internation coef.     Internation coef.     Internation coef.     Internation coef.     Internation coef.       Internation coef.     Internation coef.     Internation coef.     Internation coef.     Internation coef.       Internation coef.     Internation coef.     Internation coef.     Internation coef.     Internation coef.       Internation coef.     Internation coef.     Internation coef.     Internation coef.     Internation coef.       Internation coef.     Internation coef.     Internation coef.     Internation coef.     Internation coef.       Internation coef.     Internation coef.     Internation coef.<	Fig 6-9 a-s		<ul> <li>Plot of baseline NfL vs</li> </ul>	Overall	CDR®+NACC-FTLD-SB	x
(30)       Gastime processing procesprecessing processing processing processing processing p	(80)		baseline notential correlate	overall	CDR®+NACC-FTI D-SB + Motor	X
<ul> <li>Plot of NIL random intercept sys.random intercept potential correlate + correlation coefs.</li> <li>Plot of baseline NL vs. rate of progression potential correlate + correlation coef.</li> <li>Plot of rate of progression NfL vs. rate of progression potential correlate + correlation coefs.</li> <li>Plot of rate of progression potential correlate to estimate correlation coveriance for marginal correlation</li> <li>Plot of marginal correlation between NIL and potential correlation</li> <li>Plot of marginal correlation between NIL and potential correlation</li> <li>Plot of Targinal correlation between NIL and potential correlation</li> <li>Plot of CDR®+NACC-FTLD-SB</li> <li>Summary of NIL (baseline progression PML (baseline) potentine correlation space many of NIL (baseline) progression</li> <li>Fig 11 a - d (3)</li> <li>G.3.3 NIL Prediction of Summary of NIL (baseline) progression</li> <li>Fight a - d (a)</li> <li>G.3.3 NIL Prediction of Summary of NIL (baseline) progression</li> <li>Summary of NIL (baseline)</li></ul>	(00)		+ correlation coef.			~
Analysis 4 a-s (20)     6.3.2 NIL Fig 10 a-s (20)     6.3.2 NIL Fig 11 a - d (4)     6.3.3 Summary of NL (baseline progression potential correlate + correlation coef.     0verall NIL Prediction of Plot of rate of progression potential correlate + correlation coef.     NIL Plot of rate of progression potential correlate to estimate correlations between subject-level random intercepts and rates of change and their covariance for marginal correlation     Overall     NIL, Clinical and MRI Correlates (20)     NIL Plot of marginal correlation       Fig 10 a-s (20)     6.3.2 Plot of CDR@+NACC-FTLD-SB     NIL Summary of NIL (baseline and rate of change) by cluster overall and by mutation group progression of progression     Overall     NIL, CDR@+NACC-FTLD-SB     Intercepts and plot of CDR@+NACC-FTLD-SB       Table 8'     6.3.3 NIL Prediction of Converters at 1, 2, and 3 of Converters at 1, 2, and 3 of Conversion     Non-     NIL z-score, CDR@+NACC-FTLD-			<ul> <li>Plot of NfL random</li> </ul>		UDS3-EF Composite Score	Х
Intercept potential corelate + correlation coefs.Clinical Correlates Secondary (7)Plot of baseline NfL vs. rate of progression potential correlate + correlation coef.Frontal MRI ROIXAnalysis 4 a-s (20)·Plot of rate of progression potential correlate + correlation coefs.NfL, vs. rate of progression potential correlate + correlation coefs.NfL, Clinical and MRI Correlates (20)Image: clinical correlate + correlation coefs.Analysis 4 a-s (20)Bivariate LME Analysis of NL and potential correlate to estimate correlation between subject-level random intercepts and rates of change and their correlation potential correlationOverallNfL, Clinical and MRI Correlates (20)Image: clinical correlates (20)Fig 10 a-s (20)6.3.2 NfL Prediction of Rate of progressionCluster Analysis Overall and by Usation group Out into correlate ode of change of NfL (baseline NfL section correlate ode of change of NfL (baseline) S over time color coded by cluster overall and by baseline NfL (baseline NfL S soure time of coded by cluster overall and by baseline NfL (baseline NfL progressionNon- symptomaticNfL, CDR@+NACC-FTLD-SBTable 66.3.3 NfL Prediction of ASummary of NfL (baseline) symptomaticNon- symptomaticNfL, CDR@+NACC-FTLD-Clobal symptomaticTable 8'6.3.3 ConversionSummary of NfL (baseline) symptomaticNon- symptomaticNfL, Score, CDR@+NACC-FTLD-			intercepts vs. random		L L	
Image: correlate + correlation coefs.Plot of baseline NfL vs. rate of progression potential coef.Frontal MRI ROIXTemporal MRI ROIXAnalysis 4 a-s (20)• Plot of rate of progression potential correlate + correlation coefs.• NerallNRI. Correlates Secondary (8)Bitvariate LME Analysis of NL and potential correlate to estimate correlation correlation correlation coefs.• NerallNRI. Clinical and MRI Correlates (20)Fig 10 a-s (20)Bitvariate LME Analysis of NL and potential correlate to estimate correlation of marginal correlation correlation correlation correlation• NerallNRI. Clinical and MRI Correlates (20)Fig 10 a-s (20)• NIL Plot of marginal correlation correlate over time of change and their covariance for marginal correlate over time• OverallNIL, Clinical and MRI Correlates (20)Fig 11 a - d (4)• Summary of ML (baseline and rate of change ly by Cluster overall and by mutation group• OverallNIL, CDR@+NACC-FTLD-SBFig 11 a - d (4)• Summary of NL (baseline and change from baseline NL of custer overall and by mutation type, and change from baseline NL of converters van on- converters van on- correlate over time color coded by cluster overall and by mutation type, and change from baseline NL of converters van on- converters van on			intercept potential		Clinical Correlates Secondary (7)	
coefs.coefs.Frontal MRI ROIXTemporal MRI ROIXTemporal MRI ROIXMRI Correlates Secondary (8)Plot of rate of progression potential correlate + correlation coefs.MRI Correlates Secondary (8)Analysis 4 a-s (20)Bivariate LME Analysis of NL and potential correlate to estimate Correlations between subject-level random intercepts and rates of change and their covariance for marginal correlate or timeOverallNfL, Clinical and MRI Correlates (20)Fig 10 a-s (20)OverallNfL, Clinical and MRI Correlates (20)Plot of marginal covariance for marginal correlation between subject-level random intercepts and rates of change and their covariance for marginal correlate over timeOverallNfL, Clinical and MRI Correlates (20)Fig 10 a-s (20)Cluster AnalysisOverallNfL, Clinical and MRI Correlates (20)Image: Cluster AnalysisFig 11 a - d (4)NfL progressionSummary of NL (baseline and rate of change) by Cluster overall and by mutation type, and change from baseline NL and ch			correlate + correlation			
<ul> <li>Pilot of baseline NfL vs. rate of progression potential correlate + correlation coef.</li> <li>Pilot of rate of progression potential correlate + correlation coef.</li> <li>Pilot of rate of progression potential correlate + correlation coef.</li> <li>Bivariate LME Analysis of NfL and potential correlate to estimate correlations between subject-level random intercepts and rates of change and their covariance for marginal correlate or estimate correlation coefficient and potential correlation between subject-level random intercepts and rates of change and their covariance for marginal correlation between subject-level random intercepts and rates of change and their covariance for marginal correlation between NfL and potential correlate or estimate correlation potential correlate or discussion of fate of progression potential and by mutation group</li> <li>Fig 11 a - d (4)</li> <li>Fig 11 a - d (A)</li> <li>Table 8'</li> <li>Conversion</li> <li>Fig 43</li> <li>Conversion</li> <li>NfL (baseline model) progression of NfL (baseline model) progression protectial and by baseline NfL ws. non- onverters vs. non- converters vs. non- converters vs. non- converting vs. non- symptomatic</li> <li>NfL cDR®+NACC-FTLD-Global symptomatic</li> </ul>			coefs.		Frontal MRI ROI	Х
Analysis 4 a-s (20)of progression potential correlate + correlation coef.Temporal MRI ROIXAnalysis 4 a-s (20)• Plot of rate of progression notential correlate + correlation coefs.NfL, sc. rate of progression notential correlate + correlation corelate + correlation correlate + correlation correlate - correlation correlate - correlation correlate - correlation correlate - correlation correlate - correlation between subject-level random intercepts and rates of change and their correlationOverallNfL, Clinical and MRI Correlates (20)Fig 10 a-s (20)6.3.2Cluster AnalysisOverall orrelationNfL, Clinical and MRI Correlates (20)Fig 11 a - d (4)NfL Prediction of Rate of progressionCluster Analysis progressionOverall overall and potential correlationNfL, Clinical and MRI Correlates (20)Fig 11 a - d (4)NfL Prediction of Rate of progressionCluster Analysis progressionOverall overall and by baseline NfL cluster overall and by baseline NfL cluster overall and by baseline NfL, mutation type, and change from baseline NfL orrelationNfL, CDR@+NACC-FTLD-SBTable 7 NL Prediction of NR ConversionSummary of NfL (baseline) progressionNon- symptomaticNfL, CDR@+NACC-FTLD-Global symptomaticTable 8* ConversionSummary of NfL (baseline) prediction of converters vs. non- converters vs			• Plot of baseline NfL vs. rate			
Analysis 4 a-s       Corelation coefs.       MRI Correlates Secondary (8)         Analysis 4 a-s       Plot of rate of progression NfL vs. rate of progression potential correlate + correlation coefs.       NfL, Clinical and MRI Correlates         Bivariate LME Analysis of NfL (20)       Bivariate LME Analysis of NfL and potential correlate or estimate correlations between subject-level random intercepts and rates of change and their covariance for marginal correlation between NL and potential correlation between NL and potential correlation between NL and potential correlation of crue time       Overall       NfL, Clinical and MRI Correlates (20)         Fig 10 a-s       6.3.2       Cluster Analysis       Overall       NfL, CDR@+NACC-FTLD-SB         Fig 11 a - d       Plot of CDR@+NACC-FTLD-SB       Overall       NfL, CDR@+NACC-FTLD-SB         Fig 11 a - d       Summary of NRL (baseline and call on by baseline NL, mutation type, and change by cluster overall and by baseline NL, mutation type, and change from baseline NL.       Overall       NfL, CDR@+NACC-FTLD-SB         Table 7       6.3.3       Summary of NRL (baseline) of for converters vs. non-converters vs. non-converter			of progression potential		Temporal MRI ROI	Х
Analysis 4 a-s (20)       Plot of rate of progression potential correlate + correlation coefs.       NRL, Strate of progression potential correlate + correlation coefs.       NRL, Clinical and MRI Correlates (20)         Fig 10 a-s (20)       Bivariate LME Analysis of NL and potential correlate to estimate correlations between subject-level random intercepts and rates of change and their covariance for marginal correlation       Overall       NRL, Clinical and MRI Correlates (20)         Fig 10 a-s (20)       Plot of marginal correlation between NFL and potential correlation       Overall       NRL, Clinical and MRI Correlates (20)         Fig 11 a -d (4)       6.3.2 NRL Prediction of Rate of progression       Cluster Analysis Outser overall and by cluster overall and by cluster overall and by baseline NL, mutation group       NRL, CDR@+NACC-FTLD-SB         Fig 11 a - d (4)       6.3.3 NRL Prediction of Rate of progression       Summary of NL (baseline) NRL Correlates ver, non- converters vs, non- converters v			coef		MDL Completes Coson dom: (0)	
Analysis 4 a-s (20)NfL vs. rate of progression potential correlate + correlation coefs.OverallNfL, Clinical and MRI Correlates (20)Analysis 4 a-s (20)Bivariate LME Analysis of NfL and potential correlate to estimate correlations between subject-level random intercepts and rates of change and their covariance for marginal correlationOverallNfL, Clinical and MRI Correlates (20)Fig 10 a-s (20)Plot of marginal correlation between NfL and potential correlation between NfL and potential correlation between NfL and potential correlation perdiction of Rate of progressionOverallNfL, Clinical and MRI Correlates (20)Fig 11 a - d (4)NfL Plot of CDR@+NACC-FTLD- SB over time color coded by cluster overall and by baseline NfL, mutation type, and change from baseline NfLOverallNfL, CDR@+NACC-FTLD-SBFig 11 a - d (4)Summary of ML (baseline) progressionNon- symptomatic symptomaticNfL, CDR@+NACC-FTLD-Global symptomaticTable 8*ConversionSummary of NfL (baseline) sumary of NfL (baseline)Non- symptomaticNfL, CDR@+NACC-FTLD- Symptomatic			• Plot of rate of progression		MRI Correlates Secondary (8)	
Analysis 4 a-s (20)potential correlate + correlation coefs.OverallNfL, Clinical and MRI Correlates (20)Fig 10 a-s (20)estimate correlations between subject-level random intercepts and rates of change and their covariance for marginal correlationOverallNfL, Clinical and MRI Correlates (20)Fig 10 a-s (20)Plot of marginal correlation between NfL and potential correlationOverallNfL, Clinical and MRI Correlates (20)Analysis 5 Table 66.3.2 NfL prediction of Rate of progressionCluster AnalysisOverallNfL, CDR@+NACC-FTLD-SBFig 11 a - d (4)NfL Plot of CDR@+NACC-FTLD- SB over time color coded by cluster overall and by mutation groupOverallNfL, CDR@+NACC-FTLD-SBTable 7 Calser NfL Prediction of R4 VFLSummary of NfL (baseline) nutation groupNon- symptomaticNfL, CDR@+NACC-FTLD-Global symptomaticTable 8*ConversionSummary of NfL (baseline) of or converters vs. non- for conv			NfL vs. rate of progression			
Analysis 4 a-s (20)Correlation coefs.Image: correlation coefs. <th< th=""><th></th><th></th><th>potential correlate +</th><th></th><th></th><th></th></th<>			potential correlate +			
Analysis 4 a-s (20)Bivariate LME Analysis of NfL and potential correlate to estimate correlations between subject-level random intercepts and rates of change and their covariance for marginal correlationOverallNfL, Clinical and MRI Correlates (20)Fig 10 a-s (20)Plot of marginal correlation between NfL and potential correlationOverallNfL, Clinical and MRI Correlates (20)Fig 10 a-s (20)Flot of marginal correlation between NfL and potential correlate over timeOverallNfL, Clinical and MRI Correlates (20)Analysis 56.3.2 NfL Prediction of Rate of progressionCluster AnalysisOverallNfL, CDR@+NACC-FTLD-SBFig 11 a - d (4)NfL NfL Cluster over all and by mutation groupOverallNfL, CDR@+NACC-FTLD-SBFig 11 a - d (4)SB over time color coded by cluster over all and by baseline NfLOverallCDR@+NACC-FTLD-SBTable 76.3.3 NfL Prediction of Prediction of Prediction of SB over time color coded by cluster over all and by baseline NfLNon- symptomaticNfL, CDR@+NACC-FTLD-Global symptomaticTable 76.3.3 NfL Prediction of Prediction of Prediction of Prediction of Prediction of Summary of NfL (baseline) Summary of NfL (baseline) NfL Prediction of Prediction of Prediction of Prediction of Summary of NfL (baseline)Non- symptomaticNfL cDR@+NACC-FTLD-Global SymptomaticTable 8*ConversionSummary of NfL (baseline) Prediction of Prediction Summary of NfL (baseline)Non- Sym			correlation coefs.			
(20) (20) (20)and potential correlate to estimate correlations between subject-level random intercepts and rates of change and their covariance for marginal correlation(20)(20)Fig 10 a-s (20)Plot of marginal correlation between NfL and potential correlate over timeOverallNfL, Clinical and MRI Correlates (20)Analysis 56.3.2 NfL Prediction of Rate of progressionCluster Analysis ML Plot of CDR®+NACC-FTLD- SB over time color coded by cluster overall and by mutation groupOverallNfL, CDR®+NACC-FTLD-SBFig 11 a - d (4)Plot of CDR®+NACC-FTLD- SB over time color coded by cluster overall and by mutation groupOverallCDR®+NACC-FTLD-SBTable 76.3.3 NfL Prediction of query space from baseline NL progressionSummary of NfL (baseline not covereters vs. non- converters vs.	Analysis 4 a-s		Bivariate LME Analysis of NfL	Overall	NfL, Clinical and MRI Correlates	
Fig 10 a-s (20)estimate correlations between subject-level random intercepts and rates of change and their covariance for marginal correlationOverallNfL, Clinical and MRI Correlates (20)Fig 10 a-s (20)6.3.2Cluster AnalysisOverallNfL, Clnical and MRI Correlates (20)Analysis 56.3.2Cluster AnalysisOverallNfL, CDR®+NACC-FTLD-SBTable 6NfL Prediction of Rate of progressionSummary of NfL (baseline and rate of change) by Cluster overall and by mutation groupOverallNfL, CDR®+NACC-FTLD-SBFig 11 a - d (4)Plot of CDR®+NACC-FTLD- SB over time color coded by cluster overall and by baseline NfLOverallCDR®+NACC-FTLD-SBTable 76.3.3 NGL predictionSummary of NfL (baseline) nd change from baseline NfLNon- symptomatic symptomaticNfL, CDR®+NACC-FTLD-Global symptomaticTable 8*ConversionSummary of NfL (baseline) of versi st 1, 2, and 3Non- symptomaticNfL z-score, CDR®+NACC-FTLD-	(20)		and potential correlate to		(20)	
Fig 10 a-s (20)between subject-level random intercepts and rates of change and their covariance for marginal correlationOverallNfL, Clinical and MRI Correlates (20)Fig 10 a-s (20)Plot of marginal correlation between NfL and potential correlate over timeOverallNfL, Clinical and MRI Correlates (20)Analysis 56.3.2 Prediction progressionCluster AnalysisOverallNfL, CDR@+NACC-FTLD-SBTable 6NfL progression mutation groupSummary of NfL (baseline and rate of change) by Cluster overall and by mutation groupOverallNfL, CDR@+NACC-FTLD-SBFig 11 a - d (4)Plot of CDR@+NACC-FTLD- SB over time color coded by cluster overall and by baseline NfL, mutation type, and change from baseline NfLOverallCDR@+NACC-FTLD-SBTable 76.3.3 NfL for converters vs. non- converters vs. non- <br< th=""><th></th><th></th><th>estimate correlations</th><th></th><th></th><th></th></br<>			estimate correlations			
Fig 10 a-s (20)Cluster AnalysisOverallNfL, Clinical and MRI Correlates (20)Analysis 56.3.2 NfL Prediction of Rate of progressionCluster AnalysisOverallNfL, CDR®+NACC-FTLD-SBFig 11 a - d (4)NfL Plot of CDR®+NACC-FTLD- SB over time color coded by cluster overall and by baseline NfL, mutation type, and change from baseline NfLOverallNfL, CDR®+NACC-FTLD-SBTable 76.3.3 NfL Prediction of Rate of progressionSummary of NfL (baseline) of CDR®+NACC-FTLD- SB over time color coded by cluster overall and by baseline NfL, mutation type, and change from baseline NfLNon- symptomaticNfL, CDR®+NACC-FTLD-Global symptomaticTable 8*ConversionSummary of NfL (baseline) prediction of SB over time color coded by cluster overall and by baseline NfLNon- symptomaticNfL, CDR®+NACC-FTLD-Global symptomaticTable 8*ConversionSummary of NfL (baseline) predictionNon- symptomaticNfL z-score, CDR®+NACC-FTLD-			between subject-level			
Fig 10 a-s (20)6.3.2 Prediction of Rate of progressionCluster AnalysisOverall overallNfL, CDR®+NACC-FTLD-SBFig 11 a - d (4)NfL Prediction of Rate of progressionCluster AnalysisOverallNfL, CDR®+NACC-FTLD-SBFig 11 a - d (4)NfL Prediction of Rate of progressionSummary of NfL (baseline) solution groupOverallNfL, CDR®+NACC-FTLD-SBTable 7 of of of cluster6.3.3 progressionSummary of NfL (baseline) of CDR®+NACC-FTLD- SB over time color coded by cluster overall and by mutation groupOverallNfL, CDR®+NACC-FTLD-SBTable 7 of of of cluster6.3.3 NfL prediction of scale in which with the prediction sale in which with the prediction of covere and the progressionNon- symptomaticNfL, CDR®+NACC-FTLD-SBTable 8*ConversionSummary of NfL (baseline) years by mutationNon- symptomaticNfL z-score, CDR®+NACC-FTLD-			random intercepts and rates			
Fig 10 a-s (20)CoveralitionOverallNfL, Clinical and MRI Correlates (20)Analysis 56.3.2 NfL Prediction of Rate of progressionCluster AnalysisOverallNfL, CDR®+NACC-FTLD-SBTable 6NfL Prediction of Rate of progressionCluster AnalysisOverallNfL, CDR®+NACC-FTLD-SBFig 11 a - d (4)NfL Prediction of Rate of progressionPlot of CDR®+NACC-FTLD- SB over time color coded by cluster overall and by mutation type, and change from baseline NfLOverallCDR®+NACC-FTLD-SBTable 76.3.3 NfL Prediction of NfL Prediction of NfLSummary of NfL (baseline) (baseline) SB over time color coded by cluster overall and by baseline NfL, mutation type, and change from baseline NfLNon- symptomaticNfL, CDR®+NACC-FTLD-Global symptomaticTable 8*Conversion Summary of NfL (baseline) Summary of NfL (baseline) Summary of NfL (baseline) Non-Non- symptomaticNfL, CDR®+NACC-FTLD-Global symptomatic			of change and their			
Fig 10 a-s (20)For feration Pot of marginal correlation between NL and potential correlate over timeOverallNfL, Clinical and MRI Correlates (20)Analysis 56.3.2Cluster AnalysisOverallNfL, CDR®+NACC-FTLD-SBTable 6NfL Prediction of Rate of progressionSummary of NfL (baseline and rate of change) by Cluster overall and by mutation groupOverallNfL, CDR®+NACC-FTLD-SBFig 11 a - d (4)Plot of CDR®+NACC-FTLD- SB over time color coded by cluster overall and by baseline NfL, mutation type, and change from baseline NfLOverallCDR®+NACC-FTLD-SBTable 76.3.3 NfL Prediction of Rediction of NfL SB correters vs. non- of Years by mutationNon- symptomaticNfL, CDR®+NACC-FTLD-Global symptomaticNfL, CDR®+NACC-FTLD-Global symptomaticTable 8*ConversionSummary of NfL (baseline) years by mutationNon- symptomaticNfL z-score, CDR®+NACC-FTLD-			covariance for marginal			
Table 5 (20)6.3.2 NfL Prediction of Rate of progressionCluster Analysis NfL Pot of CDR®+NACC-FTLD-SBOverallNfL, CDR®+NACC-FTLD-SBFig 11 a - d (4)NfL Prediction of Rate of progressionSummary of NfL (baseline and rate of change) by Cluster overall and by mutation groupOverallNfL, CDR®+NACC-FTLD-SBFig 11 a - d (4)Plot of CDR®+NACC-FTLD- SB over time color coded by cluster overall and by mutation type, 	Fig 10 a-s		Plot of marginal correlation	Overall	NfL Clinical and MRI Correlates	
Analysis 56.3.2 NfL Prediction of Rate of progressionCluster Analysis Summary of NfL (baseline and rate of change) by Cluster overall and by mutation groupOverallNfL, CDR®+NACC-FTLD-SBFig 11 a - d (4)Plot of CDR®+NACC-FTLD- SB over time color coded by cluster overall and by baseline NfL, mutation type, and change from baseline NfLOverallOverallTable 76.3.3 NfL Prediction of a6.3.3 for converters st 1, 2, and 3 of vears by mutationNon- symptomaticNfL, CDR®+NACC-FTLD-Global symptomaticTable 8*ConversionSummary of NfL (baseline) summary of NfL (baseline) Summary of NfL (baseline)Non- symptomaticNfL z-score, CDR®+NACC-FTLD- Summary of NfL (baseline)	(20)		between NfL and potential	overall	(20)	
Analysis 56.3.2Cluster AnalysisOverallNfL, CDR®+NACC-FTLD-SBTable 6NfL Prediction of Rate of progressionSummary of NfL (baseline and rate of change) by Cluster overall and by mutation groupOverallNfL, CDR®+NACC-FTLD-SBFig 11 a - d (4)Plot of CDR®+NACC-FTLD- SB over time color coded by cluster overall and by baseline NfL, mutation type, and change from baseline NfLOverallCDR®+NACC-FTLD-SBTable 76.3.3 NfL Prediction of of of SBSummary of NfL (baseline) for converters vs. non- converters at 1, 2, and 3 years by mutationNon- symptomaticNfL, CDR®+NACC-FTLD-Global symptomaticTable 8*ConversionSummary of NfL (baseline) Summary of NfL (baseline)Non- symptomaticNfL z-score, CDR®+NACC-FTLD-	()		correlate over time			
Table 6NfL Prediction of Rate of progressionSummary of NfL (baseline and rate of change) by Cluster overall and by mutation groupOverallNfL, CDR®+NACC-FTLD-SBFig 11 a - d (4)Plot of CDR®+NACC-FTLD- SB over time color coded by cluster overall and by baseline NfL, mutation type, and change from baseline NfLOverallCDR®+NACC-FTLD-SBTable 76.3.3 NfL Prediction of of Of NfLSummary of NfL (baseline) for converters vs. non- converters at 1, 2, and 3 years by mutationNon- symptomaticNfL, CDR®+NACC-FTLD-GlobalTable 8*ConversionSummary of NfL (baseline) Summary of NfL (baseline)Non- symptomaticNfL z-score, CDR®+NACC-FTLD- SUmmary of NfL (baseline)	Analysis 5	6.3.2	Cluster Analysis	Overall	NfL, CDR®+NACC-FTLD-SB	
Prediction of Rate of progressionand rate of change) by Cluster overall and by mutation groupAnd rate of change) by Cluster overall and by mutation groupAnd rate of change) by Cluster overall and by Mutation groupFig 11 a - d (4)Plot of CDR®+NACC-FTLD- SB over time color coded by cluster overall and by baseline NfL, mutation type, and change from baseline NfLOverallCDR®+NACC-FTLD-SBTable 76.3.3 NfL for converters vs. non- of ofSummary of NfL (baseline) symptomaticNon- symptomaticNfL, CDR®+NACC-FTLD-GlobalTable 8*ConversionSummary of NfL (baseline) summary of NfL (baseline)Non- symptomaticNfL z-score, CDR®+NACC-FTLD-	Table 6	NfL	Summary of NfL (baseline	Overall	NfL, CDR®+NACC-FTLD-SB	
of Rate of progressionCluster overall and by mutation groupImage: Cluster overall and by mutation groupFig 11 a - d (4)Plot of CDR®+NACC-FTLD- SB over time color coded by cluster overall and by baseline NfL, mutation type, and change from baseline NfLOverallCDR®+NACC-FTLD-SBTable 76.3.3 NfLSummary of NfL (baseline) for converters vs. non- of ofNon- symptomaticNfL, CDR®+NACC-FTLD-GlobalTable 8*ConversionSummary of NfL (baseline) summary of NfL (baseline)Non- symptomaticNfL z-score, CDR®+NACC-FTLD-		Prediction	and rate of change) by			
progressionmutation groupImage: constraint of the second se		of Rate of	Cluster overall and by			
Fig 11 a - d (4)Plot of CDR®+NACC-FTLD- SB over time color coded by cluster overall and by baseline NfL, mutation type, and change from baseline NfLOverallCDR®+NACC-FTLD-SBTable 76.3.3Summary of NfL (baseline) for converters vs. non- of ofNon- symptomaticNfL, CDR®+NACC-FTLD-GlobalTable 8*ConversionSummary of NfL (baseline)Non- symptomaticNfL z-score, CDR®+NACC-FTLD-		progression	mutation group			
(4)SB over time color coded by cluster overall and by baseline NfL, mutation type, and change from baseline NfLImage: Convertion of the convertion	Fig 11 a - d		Plot of CDR®+NACC-FTLD-	Overall	CDR®+NACC-FTLD-SB	
rable 7       6.3.3       Summary of NfL (baseline)       Non-       NfL, CDR®+NACC-FTLD-Global         Prediction       for converters vs. non-       symptomatic         of       years by mutation       Non-         Table 8*       Conversion       Summary of NfL (baseline)	(4)		SB over time color coded by			
Table 7       6.3.3       Summary of NfL (baseline)       Non-       NfL, CDR®+NACC-FTLD-Global         NfL       for converters vs. non-       symptomatic         Prediction       converters at 1, 2, and 3          of       years by mutation       Non-         Table 8*       Conversion       Summary of NfL (baseline)			cluster overall and by			
Table 7       6.3.3       Summary of NfL (baseline)       Non-       NfL, CDR®+NACC-FTLD-Global         NfL       for converters vs. non-       symptomatic         Prediction       converters at 1, 2, and 3       of         of       years by mutation       Non-         Table 8*       Conversion       Summary of NfL (baseline)       Non-			baseline NfL, mutation type,			
Non-     NTL, CDR®+NACC-FILD-Global       NfL     for converters vs. non-     symptomatic       Prediction     converters at 1, 2, and 3     symptomatic       of     years by mutation     Non-     NfL z-score, CDR®+NACC-FTLD-Global	Table 7	(22	and change from baseline NfL	Non		
NL     for converters vs. non-     symptomatic       Prediction     converters at 1, 2, and 3     symptomatic       of     years by mutation     symptomatic       Table 8*     Conversion     Summary of NfL (baseline)     Non-     NfL z-score, CDR®+NACC-FTLD-	Table 7	0.3.3 NE	Summary of NIL (baseline)	NON-	NIL, UDK®+NAUC-FTLD-Global	
Interaction     Conversion     Conversion       of     years by mutation       Table 8*     Conversion       Summary of NfL (baseline)     Non-       NfL z-score, CDR®+NACC-FTLD-		NIL	for converters vs. non-	symptomatic		
Table 8*         Conversion         Summary of NfL (baseline)         Non-         NfL z-score, CDR®+NACC-FTLD-		of	vears by mutation			
	Table 8*	Conversion	Summary of NfL (baseline)	Non-	NfL z-score CDR®+NACC-FTI D-	
age-adjusted z-score for symptomatic Global	- 4010 0		age-adjusted z-score for	symptomatic	Global	

\* Analysis of age-adjusted NfL z-scores dependent on sufficient data availability for standardization

	converters vs. non- converters at 1, 2, and 3 years by mutation			
Figure 12 a-c	ROC curves for prediction o	Non-	NfL, CDR®+NACC-FTLD-Global	
(3)	1, 2, and 3 year conversion using baseline NfL by mutation	symptomatic		
Figure 13	Kaplan-Meier curves of time to conversion stratified by quintiles of baseline NfL wit summarizes of probability of remaining asymptomatic or pre-symptomatic at 1 year, years, and 3 years	Non- symptomatic f	NfL, CDR®+NACC-FTLD-Global	